These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 28176270)

  • 21. [Advances in polymer-drug conjugated micelles in the delivery of anticancer drugs].
    Yin XL; Zhang B; Liu YJ; Zhang N
    Yao Xue Xue Bao; 2016 May; 51(5):710-6. PubMed ID: 29874007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles.
    Hanafi-Bojd MY; Ansari L; Malaekeh-Nikouei B
    Ther Deliv; 2016 Sep; 7(9):649-55. PubMed ID: 27582236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self assembled dual responsive micelles stabilized with protein for co-delivery of drug and siRNA in cancer therapy.
    Aji Alex MR; Nehate C; Veeranarayanan S; Kumar DS; Kulshreshtha R; Koul V
    Biomaterials; 2017 Jul; 133():94-106. PubMed ID: 28433941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy.
    Li J; Liang H; Liu J; Wang Z
    Int J Pharm; 2018 Jul; 546(1-2):215-225. PubMed ID: 29787895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymer-Drug Conjugates for Anticancer Drug Delivery.
    Wadhwa S; Mumper RJ
    Crit Rev Ther Drug Carrier Syst; 2015; 32(3):215-45. PubMed ID: 26080809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer.
    Salzano G; Riehle R; Navarro G; Perche F; De Rosa G; Torchilin VP
    Cancer Lett; 2014 Feb; 343(2):224-31. PubMed ID: 24099916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo.
    Liu C; Liu X; Rocchi P; Qu F; Iovanna JL; Peng L
    Bioconjug Chem; 2014 Mar; 25(3):521-32. PubMed ID: 24494983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nano-Chitosan Particles in Anticancer Drug Delivery: An Up-to-Date Review.
    Kamath PR; Sunil D
    Mini Rev Med Chem; 2017; 17(15):1457-1487. PubMed ID: 28245780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells.
    Barrera G; Daga M; Ferrara B; Dianzani C; Pizzimenti S; Argenziano M; Cavalli R; Trotta F
    Curr Med Chem; 2017; 24(42):4800-4815. PubMed ID: 27919217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in mechanism-based chemotherapy drug-siRNA pairs in co-delivery systems for cancer: A review.
    Wang M; Wang J; Li B; Meng L; Tian Z
    Colloids Surf B Biointerfaces; 2017 Sep; 157():297-308. PubMed ID: 28601758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
    Beretta GL; Cavalieri F
    Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Targeting Synergistic Drug Delivery by Self-Assembled Hybrid Nanovesicles to Overcome Drug Resistance.
    Gong MQ; Wu C; He XY; Zong JY; Wu JL; Zhuo RX; Cheng SX
    Pharm Res; 2017 Jan; 34(1):148-160. PubMed ID: 27738951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Cancer Drug Delivery Using Carbohydrate-Based Polymers.
    Ranjbari J; Mokhtarzadeh A; Alibakhshi A; Tabarzad M; Hejazi M; Ramezani M
    Curr Pharm Des; 2018 Feb; 23(39):6019-6032. PubMed ID: 28482782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SiRNA/DOX lodeded chitosan based nanoparticles: Development, Characterization and in vitro evaluation on A549 lung cancer cell line.
    Seifi-Najmi M; Hajivalili M; Safaralizadeh R; Sadreddini S; Esmaeili S; Razavi R; Ahmadi M; Mikaeili H; Baradaran B; Shams-Asenjan K; Yousefi M
    Cell Mol Biol (Noisy-le-grand); 2016 Sep; 62(11):87-94. PubMed ID: 27755958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanocarriers for anticancer drugs--new trends in nanomedicine.
    Drbohlavova J; Chomoucka J; Adam V; Ryvolova M; Eckschlager T; Hubalek J; Kizek R
    Curr Drug Metab; 2013 Jun; 14(5):547-64. PubMed ID: 23687925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymeric nanoparticles as carrier for targeted and controlled delivery of anticancer agents.
    Taghipour-Sabzevar V; Sharifi T; Moghaddam MM
    Ther Deliv; 2019 Aug; 10(8):527-550. PubMed ID: 31496433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel design of a polynuclear co-delivery system for safe and efficient cancer therapy.
    Xing L; Zhang JL; Zhou TJ; He YJ; Cui PF; Gong JH; Sun M; Lu JJ; Huang Z; Jin L; Jiang HL
    Chem Commun (Camb); 2018 Aug; 54(63):8737-8740. PubMed ID: 30027958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanocarrier-based co-delivery of small molecules and siRNA/miRNA for treatment of cancer.
    Chitkara D; Singh S; Mittal A
    Ther Deliv; 2016; 7(4):245-55. PubMed ID: 27010986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in Nanocarriers for Anticancer Drugs Delivery.
    Ali I; Lone MN; Suhail M; Mukhtar SD; Asnin L
    Curr Med Chem; 2016; 23(20):2159-87. PubMed ID: 27048343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.